



PRESS RELEASE

Published: 21-06-2023

Inhalation Research Services wins new order worth 98,000 Euro from returning US customer

Inhalation Sciences AB (ISAB) has received a new order for an Inhalation Research Services (IRS) project using its predictive preclinical test module DissolvIt. The order follows a previous IRS DissolvIt project that, according to the client, was the first *in vitro* technology that enabled them to successfully predict how different Drug Candidates would perform later on in clinical trials. Predicting and preventing failure in the preclinical stage can produce enormous savings for inhaled pharmaceutical companies.

The returning client is a midsize US pharma company developing inhaled therapies. The customer has decided to test another one of its inhaled drug formulation candidates using ISAB's preclinical *in vitro* testing module DissolvIt, following successful results from its previous IRS / DissolvIt project. The new project is worth 98,000 Euro.

According to feedback received from the client, DissolvIt is the first *in vitro* dissolution method they have found that generated data of such quality that it enabled them to make reliable 'go/no-go' decisions on which formulations to proceed with in the early stages of drug development. Predicting failure at the preclinical stage can produce enormous savings in a market where, according to a 2020 study, the average cost of getting a new drug onto the market through all stages of drug development is 1.3 BUSD ¹.

The discriminative power of ISAB's DissolvIt technology in comparing small differences between drug formulations aimed for administration via inhalation, is currently being evaluated in an FDA BAA (Broad Agency Announcement) contract research project being carried out at ISAB's facilities in Sweden.

ISAB CEO Manoush Masarrat: "Our technology enables clients to get it right first time when it comes to drug development - making secure decisions on which formulations to invest further in, which to eliminate, and how best to move ahead safely in an exceptionally high-risk and costly field. This new order from a returning customer, once again reconfirms the unique predictive power of our technology – and we are delighted to welcome back this client of ours."

Discover DissolvIt®

Read ISAB's publications on DissolvIt® [here](#).

Discover DissolvIt's *in vitro* capabilities [here](#).

Explore Inhalation Research Services [here](#)

1. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054832/>

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 20 June 2023.